Biotechnology Companies in the News

Editor’s Note: The home page of the BioNJ Web site provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page (www.BioNJ.org) to read the latest news. Companies wishing to appear in the BioLines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via e-mail at BioNJ@BioNJ.org.

November 4
Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study

Antares Pharma Appoints Dr. Bruce Freundlich as Senior Vice President

ADMA Biologics Completes Enrollment of Phase III Study for RI-002

Alliance Life Sciences Participates as Event Sponsor at ISPOR 16th Annual European Congress, Presents Examination of Biotech Industry’s Performance on the Stock Market

November 2
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
October 31

Edge Therapeutics Enrolls First Patient in Phase 1/2 NEWTON Study of EG-1962 for Prevention of Delayed Cerebral Ischemia

Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call

Protalex Initiates Enrollment of Final Cohort in Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
http://www.businesswire.com/news/home/20131031005799/en/Protalex-Initiates-Enrollment-Final-Cohort-Phase-1b

electroCore’s clinical trial program into non invasive vagus nerve stimulation therapy gathers momentum

Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine

October 30

IMS Health Identifies Opportunities for Mobile Healthcare Apps to Drive Patient Engagement, Enhance Delivery of Care

Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress

Dr. Greg Koski, Head of ACRES Global Clinical Research Network, Elected to SAFE-BioPharma Board of Directors

Darren Alkins Picked to Head Alvogen Americas

Phyxius Pharma in Conjunction with Oxygen Biotherapeutics Announces New Evidence That Levosimendan Can Reduce Mortality in Heart Surgery Patients

Agano Solutions and Auditgraph Announce Advisory Board
STENTYS Self-Apposing Stent Performs Well in New Coronary Indications

Photocure provides update on Visonac®
http://www.photocure.com/Pressmedia/News/Visonac-agreement/

Lutonix Six-Month Results Presented on First IDE Trial for Drug-Coated Balloons

The Medicines Company’s EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints

October 29
RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics’ Human and Animal Study Experience

Vention Medical Acquires Fast Forward Medical

STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than Conventional Drug-Eluting Stent

Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer

Second Annual Leadership Summit for Interventional Cardiologists Held in San Francisco

October 28
Advaxis Appoints Gregory T. Mayes as Chief Operating Officer

KCI Completes Acquisition of Systagenix

NPS Pharmaceuticals to Report Third Quarter 2013 Financial Results
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1869295
Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis

Promising Phase Ib Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology

Howie Mandel Challenges People To Learn The Fibs And Facts About Atrial Fibrillation And Its Associated Increased Stroke Risk

Merck Announces Third-Quarter 2013 Financial Results

October 25

GE Healthcare Announces FDA Approval of Vizamyl™ (Flutemetamol F18 Injection) for Detection of Beta Amyloid

Additional Survival Data on Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Lung Cancer Cohort of a Phase 1 Study Presented at 15th World Conference on Lung Cancer

October 24
Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices

Celgene Reports Strong Third Quarter 2013 Operating and Financial Results

NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara® in Hypoparathyroidism
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1868017

Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes
October 23

Results for the third quarter and the first nine months 2013
http://www.photocure.com/Pressmedia/News/2Q13-Report/

Bristol-Myers Squibb Reports Third Quarter 2013 Financial Results

ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product

The Merck Manual Go-To Home Guide for Symptoms Helps Patients Assess When to Worry and When to Wait, Determine Next Steps

Senesco Opens New Clinical Trial Site at Seattle Cancer Care Alliance and is Treating the First West Coast Patient

Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study

October 22

Spectra Laboratories Enters Acquisition Agreement with Shiel Medical Laboratory

Immunomedics Reports Multiple Objective Responses in Solid Cancers With IMMU-132

Immunomedics Develops Dendritic-Cell Vaccine Technology for Lymphomas and Leukemias

Bristol-Myers Squibb to Present Data on Rheumatoid Arthritis Assets at American College of Rheumatology (ACR) 2013 Annual Meeting

Bard Announces Third Quarter Results

ADMA Biologics, Inc. Announces Closing of Initial Public Offering
Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

October 21
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing® Stent at TCT Conference

Cellbio Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings
http://ir.cellbiotherapeutics.com/releasedetail.cfm?ReleaseID=798722

Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors

October 18
Advaxis Announces Full Exercise of Underwriters’ Over-Allotment Option

Senesco Announces Reverse Stock Split

October 21
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call

ADMA Biologics, Inc. Announces Pricing of Initial Public Offering

Soligenix Announces Formation of International Melioidosis Scientific Advisory Board

October 16
Antares Announces Podium Presentation of Pivotal OTREXUP™ (methotrexate) Data at American College of Rheumatology Annual Meeting

Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference

Advaxis Announces Pricing of Public Offering of Common Stock and Warrants
October 14
**New Data from STEPS 2 Support the Long Term Use of Gattex® (Teduglutide [rDNA origin]) for Injection in Adult Patients with Short Bowel Syndrome**
http://www.npsp.com/investors-pr?txml_v=nrd&txml_nr_id=1864016

**Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in *Journal of Clinical Oncology***

**Otrexup™ (Methotrexate) Injection Approved By FDA A New Treatment For Adults With Rheumatoid Arthritis, Children With Polyarticular Idiopathic Arthritis, And Adults With Psoriasis**

October 11
**Bracco Diagnostics Inc. Makes New Syringe Packs Available for Use with EmpowerCTA® Computed Tomography Contrast Delivery Systems**
http://www.reuters.com/article/2013/10/11/nj-bracco-diagnostics-idUSnBw115725a+100+BSW20131011

October 10
**QPharma Releases Physician Sunshine Act Survey**

**PTC Therapeutics to Present at the North American Cystic Fibrosis Conference**
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=796102

**First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax® (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures**

October 9
**Lexicon Completes Pilot Study of Telotristat Etiprate In Ulcerative Colitis**

**Immunomedics Announces Termination of Agreement and Return of Worldwide Rights to Veltuzumab for All Non-Cancer Indications**

October 7
**New Findings from the REPLACE Study Suggest Natpara Has a Beneficial Effect on Bone Health in Patients with Hypoparathyroidism**
http://www.npsp.com/investors-pr?txml_v=nrd&txml_nr_id=1861915

**Natpara Pivotal Study Published in The Lancet Diabetes & Endocrinology**
http://www.npsp.com/investors-pr?txml_v=nrd&txml_nr_id=1861914
Precision Spine™ Plans to Introduce New Products at North American Spine Society Meeting in New Orleans

Cegedim Relationship Management Joins Boomer Esiason Foundation in Fight against Cystic Fibrosis at Cegedim 2013 Life Sciences Forum: Charity and Customer Collaboration Event

Report: Medical technology companies need to make radical changes to business models to stay alive

Bristol-Myers Squibb to Announce Results for Third Quarter 2013 on October 23

October 3
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development

October 2
NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting
http://www.npssp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1860848

Precision Spine™ Announces Expanded FDA 510(k) Clearance For the Reform® Pedicle Screw System

NPS Pharmaceuticals’ CEO Presents at Leerink Swann Rare Disease Roundtable Conference (Transcript)

October 1
PTC Therapeutics Expands Management Team

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus
Merck Updates Plans for Headquarters Move in New Jersey

TKL Research Adds Leadership Support for Regulatory Affairs and Scientific Services

Senesco Announces $1.725 Million Equity Financing

Celgene Corporation to Announce Third Quarter 2013 Results on October 24, 2013

Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting

Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung Cancer

Octapharma Supports Victory for Women Program, Presents Coagulation Research at 65th Annual NHF Meeting

Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Bristol-Myers Squibb to Announce Results for Third Quarter 2013 on October 23

Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace

LX4211 Achieves Positive Results In Type 2 Diabetes Patients With Renal Impairment
September 30
Amneal Pharmaceuticals to Acquire Four Generic Products

Protalex Announces Two Posters Accepted for Presentation at 2013 American College of Rheumatology Annual Meeting

PTC Therapeutics To Join Russell 2000® Index

Immunomedics Confirms Funding of Department of Defense Clinical Trial Grant for Milatuzumab in Lupus

Photocure Sponsors symposium at the 29th Congress of the Scandinavian Association of Urology and Urological Nurses

Cevira® Phase 2b results presented at the annual Colposcopy meeting in Cologne, Germany
http://www.photocure.com/Pressmedia/News/Presentation-of-Cevira-results/

Merck Animal Health’s HomeAgain® Announces Finalists for Hero of the Year Award; Voting Begins

September 28
Merck Animal Health Proudly Supports Vaccination Programs Targeted at Reducing Disease in Domestic Pets

September 27
Merck to Hold Third-Quarter 2013 Sales and Earnings Conference Call on October 28

Upcoming Presentations Related to the Lutonix Drug-Coated Balloon LEVANT 2 Trial
September 26
**New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza® (saxagliptin) SAVOR Cardiovascular Outcomes Trial Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)**

Celldex Therapeutics Announces Upcoming Presentation at the Leerink Swann Rare Disease Roundtable
http://ir.celldextherapeutics.com/releasedetail.cfm?ReleaseID=793505

QPharma’s Medical Device Division Offers Guidance on UDI Final Rule

Hooper Holmes Names Tom Collins as Chief Financial Officer

September 25
**NPS Pharmaceuticals to Present at Leerink Swann Rare Disease Roundtable**
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1857871

Bayer Senior Executive to Lead World Self-Medication Industry: Global Self-Medication Industry Association Elects Bayer HealthCare’s Erica Mann as Incoming Chair

Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield™ in GI ARS

**OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women, Now Available Nationwide**

September 24
**New Phase III Data Showed Dapagliflozin Significantly Reduced HbA1c Compared to Placebo at 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with the Combination of Metformin Plus Sulfonylurea**
http://www.reuters.com/article/2013/09/24/nj-bristol-myers-squibb-idUSnBw245372a+100+BSW20130924

September 23
**Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection**
September 19
Trifecta Clinical and SAFE-BioPharma Form Strategic Partnership to Promote Use of Standards-Based Digital Identities

Cyclacel’s Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer

Celator® Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Hematologic Malignancies

Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement

Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield™ in GI ARS

September 18
PTC Therapeutics to Present at European Pediatric Neurology Society Congress
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=791275

September 17
NPS Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1855374

Bristol-Myers Squibb Announces Dividend

Vertical Pharmaceuticals, Inc. Announces New Co-promote Agreement for Zonatuss™ (Benzonatate Capsules, USP)

Aerie Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

Diavacs Inc. Appoints Chief Medical Officer

Merck Named To 2013 Working Mother 100 Best Companies
September 16
**NJ Governor Chris Christie Visits Zoetis as Company Celebrates Establishing Strong Roots in New Jersey**

Antares Pharma Announces First Patients Dosed in VIBEX™ QS T Study Evaluating Testosterone Deficient Males

September 13
**JBK Associates International Earns Spot on Inc. 500|5000 List of America’s Fastest-Growing Private Companies for Second Consecutive Year**

September 12
**Senesco Technologies Reports Fiscal Year 2013 Financial Results**

Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy®(Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer

Celator® Pharmaceuticals Announces Listing on OTCBB and OTC Link

September 11
**Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer**

Frank E. Young, Former FDA Commissioner, Joins Braeburn Pharmaceuticals as EVP, Clinical and Regulatory Affairs

Amicus Therapeutics’ CEO John F. Crowley to Advocate for Rare and Orphan Disease Community in Washington, D.C. This Week
http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=790047

September 10
**Dr. Francois Nader, President and CEO of NPS Pharmaceuticals, Appointed to Biotechnology Industry Organization’s Board of Directors**
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1853624
Edge Therapeutics Elects Robert J. Spiegel, MD To Board of Directors

Forest Laboratories Names Brent Saunders CEO and President

Research and Markets: Osteoarthritis Pain - Pipeline Review, H2 2013

Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=789756

Phase 3 Data From The Medicines Company’s Oritavancin Solo Trials Featured at ICAAC Conference

September 9
Jubilant Clinsys Launches TrialStat eClinical Suite with Cloud Based TrialStat Orbit EDC, TrialStat CTMS and TrialStat Portal

September 6
Lexicon to Present at the Stifel Nicolaus Healthcare Conference

Celator® Pharmaceuticals to Present at Stifel Healthcare Conference 2013

U.S. Food and Drug Administration Approves ABRAXANE® in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer

September 5
Results from Phase III Study (MM-003) of Pomalidomide Plus Low-Dose Dexamethasone versus High-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma Patients Published in The Lancet Oncology

EMA Now Accepts SAFE-BioPharma Digital Signatures on eSubmissions
Protalex to Present at the Rodman & Renshaw 15th Annual Healthcare Conference

Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study

Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors

Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City

Research and Markets: Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited

Amicus Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference
http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=789060

Elusys Therapeutics Presents Efficacy Results and Other Key Findings on Eti-204 Anthrax Anti-Toxin

September 4
CR Bard to buy Rochester Medical for $262 million
http://www.reuters.com/article/2013/09/04/us-rochestermedical-offer-idUSBRE9830H520130904

Lexicon to Present at the Morgan Stanley Global Healthcare Conference

September 3
Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease

Advaxis Announces Three Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer Annual Meeting

Immunomedics Appoints Peter P. Pfreundschuh as New Chief Financial Officer
Totality of Data From Three Phase III Trials of The Medicines Company’s Intravenous Cangrelor Presented and Published

September 2
Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial

August 31
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon

August 29
Octapharma USA Announces Octaplas™ Now Available for U.S. Patients

STENTYS Reports H1 2013 Financial Results

PTC Therapeutics to Present at Upcoming Investor Conferences
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=787887

Celator® Pharmaceuticals Receives U.S. Patent on Proprietary Liposome Composition
http://www.reuters.com/article/2013/08/29/nj-celator-pharma-idUSnBw295926a+100+BSW20130829

Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease

August 28
NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

Celgene Corporation to Webcast at Upcoming Investor Conferences
August 27
**RUCDR Infinite Biologics Selects NuGEN as Corporate Sponsor and Genomic Sample Processing Partner**

Cancer Genetics, Inc. [CGIX] to Ring The NASDAQ Stock Market Opening Bell

August 26
**New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy**

Genmab Reaches Milestone in DuoBody Platform Collaboration with Janssen
http://ir.genmab.com/releasedetail.cfm?ReleaseID=787031

August 22
**Results for the second quarter and first half 2013**
http://www.photocure.com/Pressmedia/News/Photocure-ASA---Results-for-the-second-quarter-and-first-half-2013/

**Immunomedics Announces Fiscal 2013 Results**

August 21
**Exalenz Granted US Patent for Liver Application of Company’s BreathID Platform Technology**

**QPharma’s Medical Device Division Advises Manufacturers to Prepare for UDI Compliance**

August 20
**Advaxis Appoints Daniel J. O’Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board**

**Adimab Announces New Antibody Discovery Collaboration with Celgene Corporation**

**Sanofi Survey Finds Travel Puts Those with Severe Allergies on High Alert**
August 19
Aerie Pharmaceuticals Elects Murray Goldberg to the Company's Board of Directors

August 16
Merck Animal Health Strengthens Commitment to Five Steps to Responsible Beef

August 15
Celator® Announces Business Update and Fiscal Second Quarter 2013 Operational and Financial Results

Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology

August 14
Epratuzumab And Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma

Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer

Cyclacel Reports Second Quarter 2013 Financial Results

Forest Laboratories and Almirall Decide to Delay NDA Filing for Aclidinium/formoterol Combination

August 13
SAFE-BioPharma Elects Four Pharma Executives to Board of Directors

Celator® Pharmaceuticals Announces Start of Clinical Study in Patients with Untreated Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia at High Risk of Treatment-Related Mortality
NovaDel Announces Completion of the Sale of Substantially All Assets to Suda Ltd.
http://finance.yahoo.com/news/novadel-announces-completion-sale-substantially-
200100960.html

Elusys Therapeutics to Present Results on Eti-204 Anthrax Anti-Toxin

The Medicines Company Prices Public Offering of Common Stock
http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-
newsArticle&ID=1847392&highlight=

August 12
Cellnex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma
http://ir.cellnextherapeutics.com/releasedetail.cfm?ReleaseID=784514

Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs To Phase ii
Clinical Trials

ZRG Partners Global Life Sciences Hiring Index Shows Moderate 3% Growth in Q2

ADMA Biologics Reports Second Quarter 2013 Financial and Operational Results
http://www.businesswire.com/news/home/20130514006610/en/ADMA-Biologics-Reports-
Quarter-2013-Financial-Operational

PTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results

Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent
Accomplishments

The Medicines Company Announces Proposed Public Offering of Common Stock
http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-
newsArticle&ID=1847003&highlight=

Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
http://phx.corporate-ir.net/phoenix.zhtml?c=231492&p=irol-
newsArticle_print&id=1846977&highlight=

August 9
Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as
Treatment for Patients with Relapsed/Refractory Multiple Myeloma – a Rare Form of
Blood Cancer
http://newsroom.celgene.com/press-release/oral-anti-cancer-therapy-pomalidomide-now-
approved-european-commission-treatment-patie

August 8
PTC Therapeutics Announces Achievement of Major Milestone in SMA Collaboration
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=783724
NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update
http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1846411

Dendreon Announces Second Quarter 2013 Results

August 7
Antares Pharma Reports Second Quarter 2013 Operating and Financial Results

Insmed to Participate in August Investor Conferences

August 6
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference

Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results

PTC Therapeutics to Present at Wedbush Conference
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=782898

Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars

Merck & Co to Halt Production at NJ Plant and Focus on Biologics R&D
http://www.in-pharmatechnologist.com/Processing/Merck-Co-to-Halt-Production-at-NJ-Plant-and-Focus-on-Biologics-R-D

Celldex Reports Second Quarter 2013 Financial Results
http://ir.celldextherapeutics.com/releasedetail.cfm?ReleaseID=783026

August 5
Derma Sciences to Present at the Canaccord Genuity 33rd Annual Growth Conference

Aerie Pharmaceuticals Names Thomas Mitro as President and Chief Operating Officer

PTC Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=782614
The Medicines Company Announces Positive Phase III Trial Results for Fibrocaps; Completes ProFibrix Acquisition

August 2
Lexicon to Present at the Wedbush PacGrow Life Sciences Management Access Conference

Rutgers Merging Trio of Research Centers to Increase Research on Disease
http://www.njbiz.com/article/20130802/NJBIZ01/130809951/Rutgers-merging-trio-of-research-centers-to-increase-research-on-disease

July 31
Elusys Releases New Data on Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies

July 26
ADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIMA™ for the Treatment of Major Depressive Disorder in Adults

CLICK HERE to return to the main page.